The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.

Cardiovasc Diabetol · 2017 · PMC5440983 · PMID 28532406

Europe PMC DOI

hedged sentences

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

failed to achieve significancep = 0.13not close (p > 0.1)

Although it failed to achieve significance, the change in hsCRP levels among the vildagliptin group was at least double as much as the change in the metformin-only group (50% decrease vs. 20% decrease; p = 0.13; respectively).

also in 299 other papers

failed to reach significanceno p-value reported

We believe there is a strong correlation, but we failed to reach significance because of the above mentioned limitations of the study.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.